Workers' Compensation: Virus on Board: Are We Ready?

Hantavirus, the Andes Strain, and the Workers' Compensation System's Preparedness for Person-to-Person Infectious Disease Outbreaks

On May 6, 2026, the World Health Organization confirmed a cluster of Hantavirus Pulmonary Syndrome (HPS) cases aboard the cruise ship MV Hondius, an expedition vessel traveling between Argentina, Antarctica, and South Africa. Seven cases were reported—two laboratory-confirmed as Andes hantavirus (ANDV), five suspected, with three deaths and one critically ill patient. The outbreak has drawn immediate attention from virologists, epidemiologists, public health officials, and, critically, those who administer the workers' compensation system.

Unlike virtually every other hantavirus worldwide, the Andes strain has a chilling distinction: it is the only hantavirus known to be transmitted from person to person. As Professor Vincent Racaniello, Higgins Professor of Microbiology and Immunology at Columbia University, explained in his May 2026 YouTube video "Hantavirus on Board"(MicrobeTV, May 6, 2026), this characteristic places Andes virus in an entirely different epidemiological category from the Sin Nombre hantavirus circulating in the U.S. Southwest.

This blog post examines whether the workers' compensation system, still absorbing lessons from COVID-19, is equipped to handle an Andes virus or similar infectious disease outbreak, who faces occupational exposure risk, what benefits are available, and what systemic reforms are urgently needed.

Origin and Biology of the Virus

Hantaviruses are members of the family Hantaviridae, carried by rodents worldwide. In the Americas, they cause Hantavirus Cardiopulmonary Syndrome (HCPS)—a severe, rapidly onset respiratory illness. The Sin Nombre hantavirus, first identified in 1993 in the Four Corners region of the United States, is spread exclusively through contact with deer mouse excreta. It does not spread human-to-human.

The Andes virus (ANDV), first characterized in Argentina in 1995, is carried by the Oligoryzomys longicaudatus—the long-tailed pygmy rice rat—found throughout Argentina and Chile. Andes virus is the only hantavirus for which human-to-human transmission has been epidemiologically and genetically documented (Martinez et al., Emerg. Infect. Dis., 2005). Research published in Frontiers in Microbiology (Pizarro et al., 2020) demonstrates that ANDV is present in respiratory tract cells and salivary glands, consistent with respiratory and salivary transmission pathways.

Transmission of Andes virus to humans occurs most commonly through inhalation of aerosolized rodent excretions (urine, feces, saliva) in endemic areas. Unlike most hantaviruses, Andes can also spread person-to-person, primarily through close and prolonged contact—particularly among household members, intimate partners, and healthcare providers treating symptomatic patients. The WHO confirms that person-to-person transmission appears most likely during the early symptomatic phase.

Transmission Potential and Prognosis

The WHO assesses the overall public health risk from the current Andes virus outbreak as low, emphasizing that Andes does not spread as efficiently as SARS-CoV-2. Professor Racaniello explained that hantavirus's extreme lethality paradoxically limits its pandemic potential: once symptomatic, infected persons deteriorate rapidly and are quickly hospitalized, limiting their ability to transmit the virus further.

Clinical course is characterized by a febrile prodromal phase lasting 3–5 days (fever, myalgia, headache, gastrointestinal symptoms), followed by the abrupt onset of pulmonary edema, respiratory failure, and cardiovascular shock. The case fatality rate for HPS caused by ANDV ranges from 30 to 50 percent. There is no licensed vaccine and no approved antiviral treatment; supportive care in an intensive care unit remains the cornerstone of management.

Incubation ranges from 4 to 42 days (typically 2–4 weeks), meaning that exposed workers may not develop symptoms for weeks after occupational exposure. The WHO has noted that, given the extended incubation period, additional cases from the current cruise ship cluster may emerge.

Most recently in the United States, hantavirus gained public attention following reports in 2025 that Betsy Arakawa, wife of actor Gene Hackman, had died from hantavirus—illustrating that exposure can occur through everyday domestic activities in rodent-infested environments, not only through known occupational contact.

Who Faces Occupational Exposure in the United States?

Although rodents carrying Andes virus have not been found in the United States, U.S. workers face a significant occupational risk of hantavirus exposure from the domestically circulating Sin Nombre and related strains—and may be exposed to Andes virus through international travel for work, research, or expedition activities.

A landmark CDC study (de St. Maurice et al., Emerg. Infect. Dis., 2017) analyzing 22 years of HPS data found that among employed patients with confirmed HPS, 46% had jobs carrying potential frequent rodent exposure. Documented at-risk occupations include:

• Agriculture and ranching (49% of work-exposed HPS cases)

• Construction and landscaping (26% of work-exposed HPS cases)

• Forestry, parks, and outdoor recreation (9%)

• Cleaning and facilities maintenance (7%)

• Oil field workers (5%)

• Animal care workers (4%)

• Pest control technicians

• Warehouse workers (disturbing rodent-infested storage areas)

• Healthcare workers caring for ANDV-infected patients (for Andes strain)

• International expedition and ecotourism industry workers

A 2021 systematic review and meta-analysis published in Viruses (Riccò et al.) found pooled hantavirus seroprevalence rates of 3.7% in farmers and 3.8% in forestry workers—both significantly elevated compared to the general population (OR approximately 1.9 and 2.9, respectively). These figures underscore that hantavirus is a genuine, measurable occupational hazard—not a theoretical one.

Lessons from COVID-19: The Workers' Compensation System's Unfinished Business

The COVID-19 pandemic exposed deep structural vulnerabilities in the workers' compensation system's capacity to respond to infectious disease outbreaks. The core challenge: traditional workers' compensation occupational disease doctrine requires a claimant to prove that a disease arose out of and in the course of employment and is characteristic of, or peculiar to, the occupation. For airborne and contact-transmitted infectious diseases—where exposure is difficult to trace, and community spread is widespread—this proof is often impossible.

In response to COVID-19, 18 states enacted COVID-19 workers' compensation presumptions during 2020–2021, via legislation, executive orders, or emergency rules (NCCI, 2022). New Jersey's approach, for example, presumed that COVID-19 was work-related if an essential worker contracted the disease while working outside the home during a declared public health emergency. California enacted Senate Bill 1159 in 2020, creating rebuttable presumptions for specific worker categories. Federal employees were covered by modified DFEC protocols recognizing elevated occupational risk.

But these measures were reactive, not proactive. They were enacted weeks or months into the emergency, leaving frontline workers unprotected at the height of initial exposure risk. Most COVID presumptions have since expired. Tennessee and Washington took broader approaches, enacting general 'infectious disease presumptions' that could apply beyond COVID-19—but such provisions remain the exception, not the rule.

Several states proposed but did not enact permanent infectious disease presumption legislation that would apply to future pandemics. California's SB 213 would have established a standing presumption of infectious and respiratory disease for certain hospital employees, with no expiration date. None of these broader measures became law. The Andes virus outbreak is a timely reminder that the gap remains open.

Workers' Compensation Benefits Available to Hantavirus-Infected Workers

Workers who can establish occupational exposure to hantavirus—whether from contact with rodents or rodent excreta at work, or (for Andes virus) from close contact with an infected coworker or patient—may be entitled to the following workers' compensation benefits:

• Medical Benefits: All reasonable and necessary medical treatment, including emergency hospitalization, ICU care, mechanical ventilation, ECMO support, and extended rehabilitation.

• Temporary Total Disability (TTD): Wage replacement during the period of total incapacity for work, typically two-thirds of the pre-injury average weekly wage, subject to state maximum and minimum rates.

• Permanent Partial or Total Disability: Compensation for lasting pulmonary, cardiovascular, or neurological impairment that reduces earning capacity after maximum medical improvement.

• Death Benefits: Given hantavirus's fatality rate of up to 50%, surviving dependents may be entitled to burial expenses and ongoing dependency benefits under applicable state law.

• Vocational Rehabilitation: For survivors with permanent pulmonary or functional limitations that preclude return to prior employment.

The critical threshold question in any hantavirus workers' compensation claim will be whether occupational exposure, rather than community or household exposure, was a material contributing cause of the disease. For workers in high-risk occupations (agriculture, construction, pest control, healthcare) with documented worksite rodent activity or patient contact, this may be achievable. For others, the causal connection will be contested.

Under New Jersey workers' compensation law, N.J.S.A. 34:15-31, an occupational disease is compensable if it arises out of and in the course of employment and is due to causes and conditions characteristic of or peculiar to the particular trade, occupation, process or place of employment. The exposure must be in excess of the hazard to the general public. Hantavirus, given its unusual association with specific rodent-exposure occupations, is well-suited to this standard for workers in qualifying roles.

What Can the Workers' Compensation System Do to Better Prepare?

The Andes virus outbreak, Professor Racaniello's analysis, and the ECDC assessment of the MV Hondius cluster provide a clear roadmap for systemic reform:

• Enact Permanent Infectious Disease Presumption Legislation: States should adopt standing infectious disease presumptions—applicable upon a gubernatorial or public health emergency declaration—for healthcare workers, first responders, and workers in documented high-risk occupational categories, without requiring pandemic-specific legislation each time.

• OSHA Exposure Standards: OSHA should develop and issue occupational exposure standards for hantavirus and other rodent-borne zoonoses, including required PPE (N95 respirators, gloves, eye protection) for work activities involving rodent-infested areas.

• Employer Reporting and Surveillance: Mandated reporting of suspected occupational hantavirus exposures to state workers' compensation agencies and public health departments, enabling real-time surveillance of workplace-linked cases.

• Healthcare Worker Protections for Andes Virus: Given the documented person-to-person transmission of Andes virus, healthcare workers treating suspected or confirmed ANDV patients should be covered by infectious disease presumptions. Airborne and contact precautions must be specified in workplace infection control plans.

• Insurer Preparedness Planning: Workers' compensation carriers and self-insured employers should incorporate infectious disease outbreak scenarios—including novel zoonoses with occupational vectors—into their catastrophe planning and reserving frameworks.

• Proactive International Travel Policies: Employers sending workers to Argentina, Chile, Uruguay, or other ANDV-endemic regions should maintain duty-of-care protocols addressing hantavirus exposure risk, including pre-travel briefings, post-travel monitoring, and coverage confirmations under applicable workers' compensation policies.

• Funding for Vaccine and Antiviral Research: The absence of any licensed treatment for HPS represents a catastrophic gap. Federal and state governments should prioritize funding for hantavirus vaccine development and for the evaluation of ribavirin and other antiviral candidates in clinical settings.

Conclusion

The hantavirus outbreak aboard the MV Hondius is not a pandemic. Professor Racaniello is correct: Andes virus's extreme lethality limits efficient spread; this is not COVID, not influenza. But the outbreak is a vivid demonstration that novel and re-emerging infectious diseases with occupational transmission pathways will continue to challenge the workers' compensation system.

The system's COVID-19 experience revealed both its capacity for rapid adaptation—when political will exists—and its structural inability to protect workers proactively. Farm workers, construction laborers, pest control technicians, healthcare workers, and dozens of other occupational categories face measurable, documented hantavirus exposure risk every day—right now, in the United States—from domestically circulating strains.

The Andes virus outbreak should serve as a catalyst for permanent, prospective infectious-disease preparedness in workers' compensation law. The alternative, reactive legislation enacted weeks into each new outbreak, leaving workers unprotected at the moment of maximum risk, is no longer acceptable.